These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 7648763

  • 1. The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma.
    Welch RM, Brown A, Ravitch J, Dahl R.
    Clin Pharmacol Ther; 1995 Aug; 58(2):132-42. PubMed ID: 7648763
    [Abstract] [Full Text] [Related]

  • 2. Does ester hydrolysis change the in vitro degradation rate of cisatracurium and atracurium?
    Weindlmayr-Goettel M, Gilly H, Kress HG.
    Br J Anaesth; 2002 Apr; 88(4):555-62. PubMed ID: 12066733
    [Abstract] [Full Text] [Related]

  • 3. Identification of urinary and biliary conjugated metabolites of the neuromuscular blocker 51W89 by liquid chromatography/mass spectrometry.
    Dear GJ, Harrelson JC, Jones AE, Johnson TE, Pleasance S.
    Rapid Commun Mass Spectrom; 1995 Apr; 9(14):1457-64. PubMed ID: 8534894
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
    Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ.
    Anesthesiology; 1996 Feb; 84(2):300-8. PubMed ID: 8602660
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients.
    Smith CE, van Miert MM, Parker CJ, Hunter JM.
    Anaesthesia; 1997 Sep; 52(9):833-41. PubMed ID: 9349062
    [Abstract] [Full Text] [Related]

  • 6. In vitro degradation of atracurium and cisatracurium at pH 7.4 and 37 degrees C depends on the composition of the incubating solutions.
    Weindlmayr-Goettel M, Kress HG, Hammerschmidt F, Nigrovic V.
    Br J Anaesth; 1998 Sep; 81(3):409-14. PubMed ID: 9861132
    [Abstract] [Full Text] [Related]

  • 7. Importance of the organ-independent elimination of cisatracurium.
    Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR.
    Anesth Analg; 1996 Nov; 83(5):1065-71. PubMed ID: 8895287
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.
    Nigrovic V, Banoub M.
    Clin Pharmacokinet; 1992 May; 22(5):396-408. PubMed ID: 1505145
    [Abstract] [Full Text] [Related]

  • 9. Inactivation of atracurium in human and rat plasma.
    Nigrovic V, Pandya JB, Auen M, Wajskol A.
    Anesth Analg; 1985 Nov; 64(11):1047-52. PubMed ID: 2932037
    [Abstract] [Full Text] [Related]

  • 10. Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations.
    Chen C, Yamaguchi N, Varin F.
    J Vet Pharmacol Ther; 2009 Dec; 32(6):571-6. PubMed ID: 20444012
    [Abstract] [Full Text] [Related]

  • 11. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination.
    Fisher DM, Canfell PC, Fahey MR, Rosen JI, Rupp SM, Sheiner LB, Miller RD.
    Anesthesiology; 1986 Jul; 65(1):6-12. PubMed ID: 3755306
    [Abstract] [Full Text] [Related]

  • 12. In vitro degradation of atracurium in human plasma.
    Stiller RL, Cook DR, Chakravorti S.
    Br J Anaesth; 1985 Nov; 57(11):1085-8. PubMed ID: 3840382
    [Abstract] [Full Text] [Related]

  • 13. Transplacental distribution of atracurium, laudanosine and monoquaternary alcohol during elective caesarean section.
    Shearer ES, Fahy LT, O'Sullivan EP, Hunter JM.
    Br J Anaesth; 1991 May; 66(5):551-6. PubMed ID: 2031814
    [Abstract] [Full Text] [Related]

  • 14. Atracurium decay and the formation of laudanosine in humans.
    Nigrovic V, Fox JL.
    Anesthesiology; 1991 Mar; 74(3):446-54. PubMed ID: 2001023
    [Abstract] [Full Text] [Related]

  • 15. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA.
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacokinetics of cisatracurium besilate.
    Kisor DF, Schmith VD.
    Clin Pharmacokinet; 1999 Jan; 36(1):27-40. PubMed ID: 9989341
    [Abstract] [Full Text] [Related]

  • 17. Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor.
    Eng H, Niosi M, McDonald TS, Wolford A, Chen Y, Simila ST, Bauman JN, Warmus J, Kalgutkar AS.
    Xenobiotica; 2010 Jun; 40(6):369-80. PubMed ID: 20297923
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.
    Vandenbrom RH, Wierda JM, Agoston S.
    Clin Pharmacokinet; 1990 Sep; 19(3):230-40. PubMed ID: 2394062
    [Abstract] [Full Text] [Related]

  • 19. Generation of reactive metabolites during spontaneous degradation of atracurium in vitro.
    Nigrovic V, Gallup W, Pandya J, Fry K.
    Am J Med Sci; 1989 Jan; 297(1):12-7. PubMed ID: 2913796
    [Abstract] [Full Text] [Related]

  • 20. Determination of atracurium and laudanosine in human plasma by high-performance liquid chromatography.
    Varin F, Ducharme J, Besner JG, Théorêt Y.
    J Chromatogr; 1990 Aug 03; 529(2):319-27. PubMed ID: 2229251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.